What is the J and J rare disease drug called Nipocalimab (Imaavy)?
•
3 min read
Affecting approximately 300 million people worldwide, rare diseases present an immense unmet medical need that pharmaceutical companies like Johnson & Johnson (J&J) are working to address. At the heart of J&J's strategy for autoantibody-mediated rare diseases is its FcRn inhibitor, nipocalimab, now known by the brand name Imaavy, which received FDA approval for myasthenia gravis in 2025.
